# Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma

> **NCT07280832** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 188 (estimated)

## Conditions studied

- Unresectable Locally Advanced or Metastatic Melanoma

## Interventions

- **DRUG:** JMT108

## Key facts

- **NCT ID:** NCT07280832
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-17
- **Primary completion:** 2026-11-30
- **Final completion:** 2027-05-30
- **Target enrollment:** 188 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07280832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07280832, "Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07280832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*